Skip to main content
SpringerLink
Log in

Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation

  • Busulfan, Pharmacodynamics, Hepatic Veno-Occlusive Disease
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Hepatic veno-occlusive disease (HVOD) is a frequent life-threatening toxicity in patients undergoing bone marrow transplantation (BMT) after the administration of a high-dose busulfan-containing regimen. Recent studies have shown that the morbidity and mortality of HVOD may be reduced in adults by pharmacologically guided dose adjustment of busulfan. We analyzed the pharmacodynamic relationship between busulfan disposition and HVOD in 61 children (median age, 5.9 years) with malignant disease. Busulfan, given at a dose ranging from 16 mg/kg to 600 mg/m2, was combined with one or two other alkylating agents (cyclophosphamide, melphalan, thiotepa). Only 3 patients received the standard busulfan/cyclophosphamide (BUCY) regimen. A total of 24 patients (40%) developed HVOD, which resolved in all cases. A pharmacokinetics study confirmed the previously reported wide interpatient variability in busulfan disposition but did not reveal any significant alteration in children with HVOD. The mean area under the concentration-time curve (AUC) after the first dose of busulfan was higher in patients with HVOD (6,811±2,943 ng h ml−1) than in patients without HVOD (5,760±1,891 ng h ml−1;P=0.10). This difference reflects the higher dose of busulfan given to patients with HVOD. No toxic level could be defined and, moreover, none of the toxic levels identified in adults were relevant. The high incidence of HVOD in children given 600 mg/m2 busulfan may be linked to the use of more intensive than usual high-dose chemotherapy regimens and/or drug interactions. Before the prospective evaluation of busulfan dose adjustment in children, further studies are required to demonstrate firmly the existence of a pharmacodynamic relationship in terms of toxicity and allogeneic engraftment, especially when busulfan is combined with cyclophosphamide. The maximal tolerated and minimal effective AUCs in children undergoing BMT are likely to depend mainly upon the disease, the nature of the combined high-dose regimen, and the type of bone marrow transplant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Alias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E III (1992) Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 10: 995

    Google Scholar 

  2. Brugières L, Hartmann O, Benhamou E, Zafrani ES, Caillaud JM, Patte C, Kalifa C, Flamant F, Lemerle J (1988) Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow translantation in children with solid tumors: incidence, clinical course and outcome. Bone Marrow Transplant 3: 53

    Google Scholar 

  3. Gouyette A, Hartmann O, Pico J-L (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16: 184

    Google Scholar 

  4. Grochow LB (1993) Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20: 18

    Google Scholar 

  5. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen T-G, Saral R, Santos GW, Colvin OM (1989) Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25:55

    Google Scholar 

  6. Grochow B, Krivit W, Whitley LB, Blazar B (1990) Busulfan disposition in children. Blood 75: 1

    Google Scholar 

  7. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, Tötterman T, Eksborg S, Simonsson B (1989) Pharmacokinetic and metabolic studies of high-dose busulfan in adults. Eur J Clin Pharmacol 36: 525

    Google Scholar 

  8. Hassan M, Öberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, Lönnerholm G, Smedmyr B, Taube A, Wallin I, Simonsson B (1991) Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28: 130

    Google Scholar 

  9. Heidemann RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, Singler LJ, Ettinger LJ, Gillespie A, Sam J, Poplack DG (1989) Phase I and pharmacokinetic study of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49: 736

    Google Scholar 

  10. Mac Donald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED (1984) Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4: 116

    Google Scholar 

  11. Mac Donald GB, Hinds MS, Fisher LD, Schoh HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118: 255

    Google Scholar 

  12. Mansi J, Costa F da, Viner C, Judson I, Gore M, Cunningham D (1992) High-dose busulfan in patients with myeloma. J Clin Oncol 10: 1569

    Google Scholar 

  13. Méresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugières L, Lemerle J (1992) Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 10: 135

    Google Scholar 

  14. O'Dwyer PJ, La Creta F, Engstrom PF, Peter R, Tartagliaz L, Cole D, Litwin S, De Vito J, Poplack DG, De Lap RJ, Comis RL (1991) Phase I/pharmacokinetic reevaluation of thiotepa. Cancer Res 51: 3171

    Google Scholar 

  15. Peters WP, Henner WD, Grochow L, Olsen G, Edwards S, Stanbuck H, Stuart A, Gockerman J, Moore J, Bast RC, Seigler HF, Colvin OM (1987) Clinical and pharmacologic effects of high-dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 47: 6402

    Google Scholar 

  16. Ratanatharathon V, Karanes C, Lum LG, Uberti J, Dan ME, Planque MM de, Schultz KR, Cronin S, Leisz MC, Mohamed A, Sensenbrenner LL (1992) Allogeneic bone marrow transplantation in high risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Bone Marrow Transplant 9: 49

    Google Scholar 

  17. Shaw PJ, Hugh-Jones K, Hobbs JR, Downie CDC, Barnes R (1986) Busulphan and cyclophosphamide cause little early toxicity during bone marrow transplantation in fifty children. Bone Marrow Transplant 1: 193

    Google Scholar 

  18. Shaw PJ, Earl JM, Stevens MM, Bergin ME, Burgess M, Dalla Pozza L, Kellie SJ (1993) Pharmacokinetics of busulphan with single daily dosing during BMT conditioning with busulphan/cyclophosphamide (BUCY) for AML in children. Proc XXV SIOP Meet, in Med Pediatr Oncol 21: 539

    Google Scholar 

  19. Shulman HM, Hinterberger W (1992) Hepatic veno-occlusive disease — liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 10: 192

    Google Scholar 

  20. Shulman HM, Luk K, Deeg J, Shuman WB, Storb R (1987) Induction of hepatic veno-occlusive disease in dogs. Am J Pathol 126: 114

    Google Scholar 

  21. Teicher BA, Holden SA, Cuchhi CA, Cathcart KNS, Karbut TT, Flatow JL, Frei E. III (1988) Combination ofN,N′,N′',-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res 49: 94

    Google Scholar 

  22. Tranchand B, Ploin YD, Minuit MP, Spaet C, Biron P, Philip T, Ardiet C (1989) High-dose melphalan dosage adjustment: possibility of using a test-dose. Cancer Chemother Pharmacol 23: 95

    Google Scholar 

  23. Vassal G, Ré M, Gouyette A (1988) Gas chromatographic-mass spectrometry assay for busulfan in biological fluids using a deuterated internal standard. J Chromatogr 428: 357

    Google Scholar 

  24. Vassal G, Gouyette A, Hartmann O, Pico J-L, Lemerle J (1989) Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 24: 386

    Google Scholar 

  25. Vassal G, Hartmann O, Benhamou E (1990) Busulfan and veno-occlusive disease of the liver. Ann Intern Med 112: 881

    Google Scholar 

  26. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, Brugières L, Kalifa C, Gouyette A, Lemerle J (1990) Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 50: 6203

    Google Scholar 

  27. Vassal G, Deroussent A, Challine D, Hartmann O, Koscielny S, Valteau-Couanet D, Lemerle J, Gouyette A (1992) Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 79: 2475

    Google Scholar 

  28. Vassal G, Fischer A, Challine D, Boland I, Ledheist F, Lemerle S, Vilmer E, Rahimy C, Souillet G, Gluckman E, Michel G, Deroussent A, Gouyette A (1993) Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 82: 1030

    Google Scholar 

  29. Yeager AM, Wagner JE, Graham ML, Jones RJ, Santos GW, Grochow LB (1992) Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 80: 2425

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Oncology, Institut Gustave-Roussy, Rue Camille Desmoulens, F-94805, Villejuif Cedex, France

    Gilles Vassal, Dominique Valteau-Couanet, Isabelle Boland, Jean Lemerle & Olivier Hartmann

  2. Laboratory of Pharmacotoxicology and Pharmacogenetics, CNRS URA147, Institut Gustave-Roussy, Villejuif, France

    Gilles Vassal, Dominique Challine, Alain Deroussent & Alain Gouyette

  3. Department of Biostatistics and Epidemiology, Institut Gustave-Roussy, Villejuif, France

    Serge Koscielny

Authors
  1. Gilles Vassal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serge Koscielny
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dominique Challine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dominique Valteau-Couanet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Isabelle Boland
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alain Deroussent
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jean Lemerle
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alain Gouyette
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Olivier Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vassal, G., Koscielny, S., Challine, D. et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother. Pharmacol. 37, 247–253 (1995). https://doi.org/10.1007/BF00688324

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00688324

Key words

Search

Navigation